Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ajinomoto Files Suit over Actonel Generic Seeking Suspension of Sales
September 26, 2011
- Trans Genic Files Patent Application for Antibody against Novel Lung Cancer Marker
September 26, 2011
- US FDA Completes Review of Protocol for PIII Trial of Collategene: AnGes MG
September 26, 2011
- Takeda Aiming to Make Comeback in Diabetes Market
September 25, 2011
- Novartis Grows 7% Driven by New Products: President Mitani
September 22, 2011
- PIII Trial for Brain Function Imaging Agent Starts: Nihon Medi-Physics
September 21, 2011
- Nichi-Iko to Postpone M&A of Nichi-iko Pharma Factory Until June 2012
September 21, 2011
- Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015
September 21, 2011
- Kowa Yakuhin Sets Up Private Electric Generators as Part of Disaster Measures
September 20, 2011
- Sitagliptin Receives Approval for Use in Combination with Insulin: MSD, Ono
September 20, 2011
- CellCept Obtains Approval for Additional Pediatric Dosage: Chugai
September 20, 2011
- Janssen Obtains Additional Indication for Treatment-Naïve MM
September 20, 2011
- Takeda Initiates Domestic PIII Trials for Successor to Takepron
September 20, 2011
- Perampanel Improves Partial Epilepsy Seizures in Overseas PIII Trial
September 19, 2011
- Zonegran Shows High Efficacy for Pediatric Partial Epilepsy: Eisai
September 19, 2011
- NanoCarrier Obtains Substance Patent for Its “pH-Responsive Micelle” in China
September 19, 2011
- Sales of Ethical Drugs Up 0.1% in July: Crecon & Research Consulting
September 19, 2011
- Sandoz to Use Its Unique Anticancer Drug Container for More Anticancer Drugs
September 19, 2011
- Nichi-Iko, Pfizer Apply for Add’l Indication for Generic Cisplatin Using Data from Public Domain
September 19, 2011
- M3 to Start “Web Lecture” Service for Drug Makers
September 19, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…